General
Preferred name
TINIDAZOLE
Synonyms
CP12574 ()
Tindamax ()
Tinidazole ()
Symplotan ()
Tinidazol ()
Fasigin ()
NSC-758189 ()
CP-12574 ()
Tricolam ()
Simplotan ()
CP-12,574 ()
Haisigyn ()
Fasigyn ()
Trimonase ()
P&D ID
PD001375
CAS
19387-91-8
148159-84-6
Tags
available
drug
Approved by
FDA
First approval
2004
Drug indication
Bacterial infection
Bacterial vaginosis
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
HALF-LIFE
The elimination half-life is 13.2±1.4 hours and the plasma half-life is 12 to 14 hours.
ROE
Tinidazole crosses the placental barrier and is secreted in breast milk. Tinidazole is excreted by the liver and the kidneys.; Tinidazole is excreted in the urine mainly as unchanged drug (approximately 20-25% of the administered dose).; Approximately 12% of the drug is excreted in the feces.
DESCRIPTION
Tinidazole is a nitroimidazole antimicrobial compound that exhibits antiprotozoal and antibacterial (against anaerobic bacteria) activities.
(GtoPdb)
DESCRIPTION
Tinidazole, an orally available antibacterial agent, is a 5-nitroimidazole with selective activity against anaerobic bacteria and protozoa[1].
PRICE
29
DESCRIPTION
Tinidazole kills the metronidazole-susceptible isolates at a low MLC but is effective against only 4 of the 12 metronidazole-resistant isolates.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Tinidazole is a 5-nitroimidazole derivative with antiparasitic and antibiotic activity. It is used to treat trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis.
(Enamine Bioactive Compounds)
DESCRIPTION
Tinidazole (CP12574)a is a 5-nitroimidazole derivative with the antiprotozoal property. Although the mechanism of action has not been fully elucidated, it has been suggested that tinidazole is metabolized and yields nitrite anions and metronidazole. Metronidazole's nitro group, in turn, is reduced via the parasite ferredoxin, thereby generating a series of free nitro radicals including nitro anions. Toxicity is achieved via depletion of sulfhydryl groups and DNA strand breaks with multiple hits having an additive effect and ultimately leading to cell death.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
26
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
247.06
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
0.53
TPSA
95.1
Fraction CSP3
0.62
Chiral centers
0.0
Largest ring
5.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Unknown molecular target
antiprotozoal agent
Target
DNA
antibiotic
Bacterial
Parasite
Indication
giardiasis, amebiasis, bacterial vaginosis, trichomoniasis
Disease Area
infectious disease, obstetrics/gynecology
Pathway
Microbiology/virology
Anti-infection
Source data
